SITC 2022 | Pixatimod and nivolumab in metastatic melanoma, NSCLC and MSS CRC

Diwakar Davar, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, provides an overview of a Phase IIA basket study (NCT05061017) assessing pixatimod, a novel toll-like receptor 9 (TLR9) inhibitor, with nivolumab in solid tumors. Three cohorts were present, where patients with metastatic melanoma, non-small cell lung cancer and microsatellite stable (MSS) colorectal cancer (CRC) were recruited. Patients with MSS CRC were additionally given cyclophosphamide in this ongoing trial. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.